Matthew Weston
Stock Analyst at UBS
(2.79)
# 1,574
Out of 5,182 analysts
6
Total ratings
100%
Success rate
30.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Downgrades: Neutral | n/a | $43.36 | - | 1 | Jan 16, 2026 | |
| DBX Dropbox | Assumes: Sell | $29 → $27 | $25.41 | +6.26% | 1 | Sep 18, 2025 | |
| NVO Novo Nordisk | Downgrades: Neutral | n/a | $44.87 | - | 1 | Aug 5, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | n/a | $145.50 | - | 1 | Feb 13, 2025 | |
| AZN AstraZeneca | Upgrades: Buy | n/a | $181.24 | - | 2 | Feb 13, 2025 |
Sanofi
Jan 16, 2026
Downgrades: Neutral
Price Target: n/a
Current: $43.36
Upside: -
Dropbox
Sep 18, 2025
Assumes: Sell
Price Target: $29 → $27
Current: $25.41
Upside: +6.26%
Novo Nordisk
Aug 5, 2025
Downgrades: Neutral
Price Target: n/a
Current: $44.87
Upside: -
Novartis AG
Feb 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $145.50
Upside: -
AstraZeneca
Feb 13, 2025
Upgrades: Buy
Price Target: n/a
Current: $181.24
Upside: -